Clinical Trial Update: Phase IIA Study of the HDAC Inhibitor ITF2357 in Patients With JAK-2 V617F Positive Chronic Myeloproliferative Diseases [Phase 2]

View source ↗

Summary

Phase IIa study of HDAC inhibitor ITF2357 in JAK-2 V617F positive myeloproliferative diseases has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Essential Thrombocythemia
• Myelofibrosis
• Myeloproliferative Disease
• Polycythemia Vera

Drugs mentioned

• ITF2357 (ITF2357)

Snippet

Sponsor: Italfarmaco | Conditions: Myeloproliferative Diseases | Phase 2 | Status: COMPLETED | Results posted: 2019-12-03